Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain Wave-Guided nerve stimulation may tame Drug-Resistant epilepsy

NCT ID NCT04693221

First seen Feb 11, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This study tests whether fine-tuning a vagal nerve stimulator (VNS) using a brain wave measure called phase lag index (PLI) can better reduce seizures in people with epilepsy that doesn't respond to medication. About 140 participants who already have a VNS device will have their settings chosen either by the PLI method or randomly. The goal is to see if the PLI-guided settings lead to fewer seizures per month.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Clinical neurophysiology, CHU Dijon

    Dijon, France, 21079, France

  • Clinical neurophysiology, CHU Lille

    Lille, France, 59037, France

  • Department of clinical neurophysiology, Hôpital La Timone, APHM

    Marseille, France, 13885, France

  • Department of functional explorations of the nervous system, CHU

    Amiens, France, 80054, France

  • Epilepsy neurophysiopathology department, CHU Grenoble

    Grenoble, France, 38043, France

  • Epileptology Department, CHU Rennes

    Rennes, France, 35000, France

  • HCL Lyon

    Lyon, France, 69003, France

  • Hôpital St Joseph St Luc

    Lyon, FRA, 69007, France

  • Neurology Department, CHU Bordeaux

    Bordeaux, France, 33000, France

  • Neurology Department, CHU Strasbourg

    Strasbourg, France, 67098, France

  • Neurology and clinical neurophysiology, CHU Bretonneau

    Tours, France, 37044, France

  • Neuropediatrics department, CHU Angers

    Angers, France, 49933, France

  • Neurophysiological explorations, Hôpital Pierre Paul Riquet, Purpan

    Toulouse, France, 31059, France

  • Neurophysiology Department

    Paris, France, 75014, France

  • Neurophysiology Department, CHU Rouen

    Rouen, France, 76000, France

  • Neurosurgery Department, APHP

    Paris, France, 75013, France

  • Neurosurgery Department, CHRU Nancy

    Nancy, France, 54000, France

  • Neurosurgery Department, CHU Nantes

    Nantes, France, 44093, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vagal nerve stimulation (VNS) device

What this could lead to

If successful, this could provide a more effective way to set VNS devices, helping more patients with drug-resistant epilepsy have fewer seizures.

What could go wrong

This is a mid-stage study with 140 participants, and the approach is still experimental. It may not work better than standard settings, and individual responses can vary.

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.